Suppr超能文献

Fendrix疫苗在对Engerix B疫苗无反应的医护人员中的有效性。

Fendrix Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B Vaccination.

作者信息

Tejada-Pérez Juan José, Vázquez-Vicente Juan José, Herrera-Burgos María Renée, Martín-Martín Francisco Gabriel, Parrón-Carreño Tesifón, Alarcón-Rodríguez Raquel

机构信息

Faculty of Health Sciences, University of Almería, Carr. Sacramento, s/n, 04120 La Cañada, Almeria, Spain.

Risk Prevention Service, Poniente Hospital Entrepreneurial Public Health Agency, Ctra Almerimar, 31, 04700 El Ejido, Almeria, Spain.

出版信息

Vaccines (Basel). 2021 Mar 19;9(3):279. doi: 10.3390/vaccines9030279.

Abstract

Hepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with Engerix B lowers this risk by providing workers with immunity to the virus. However, through the years, we have encountered nonresponsive health personnel to the Engerix B vaccine; hence, the Occupational Health Service of Poniente Hospital studied the Fendrix adjuvanted vaccine as an alternative vaccine to develop immunological responses in healthcare workers who do not respond to vaccination with Engerix B. In our study, we employed a vaccination schedule with the Fendrix vaccine, performing serology tests on the cases after the application of each dose. The results obtained showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after the first doses. These encouraging results support the future inclusion of this vaccine as one possible alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B.

摘要

乙型肝炎(HBV)是一种病原病毒,其传播机制包括接触受感染生物体的感染血液或体液。如今,医护人员是最易接触HBV的群体之一。传统上,通过接种完整疗程剂量的安在时乙肝疫苗(Engerix B)为医护人员提供病毒免疫力,从而降低感染风险。然而,多年来,我们遇到了对安在时乙肝疫苗无反应的医护人员;因此,蓬特医院职业健康服务中心研究了芬适(Fendrix)佐剂疫苗,作为一种替代疫苗,用于对安在时乙肝疫苗接种无反应的医护人员产生免疫反应。在我们的研究中,我们采用了芬适疫苗的接种方案,在每剂接种后对病例进行血清学检测。获得的结果显示,92.3%的病例产生了体液免疫,在首剂接种后抗体滴度显著增加。这些令人鼓舞的结果支持未来将这种疫苗纳入对安在时乙肝疫苗无反应的医护人员HBV免疫接种的一种可能替代方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b392/8003400/528e51a65bc5/vaccines-09-00279-sch001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验